BMRN
Biomarin Pharmaceutical
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: BMRN
- PE Ratio
As of Jun 23, 2026, the Biomarin Pharmaceutical stock's PE ratio is 40.36. This results from the current EPS of $1.4 and stock price of $56.5. The P/E ratio has an increase of 48% from the past four quarters average of 27.2.
BMRN PE ratio history
The PE ratio of Biomarin Pharmaceutical has averaged 151.9 over the last seven years. The current PE ratio of 40.36 is 73% below the historical average. Over the past seven years, BMRN's PE ratio was at its highest in the Sep 2021 quarter at 1,288.17, when the stock price was $77.29 and the EPS was $0.06. The lowest value was in the Jun 2025 quarter, when it reached 15.98 with a price of $54.97 and an EPS of $3.44.
Biomarin Pharmaceutical PE ratio by year
Maximum annual increase: 11.78% in 2025
Maximum annual decrease: -73.04% in 2024
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 32.65 | 11.78% | $59.43 | $1.82 |
| 2024 | 29.21 | -73.04% | $65.73 | $2.25 |
| 2023 | 108.34 | -20.44% | $96.42 | $0.89 |
| 2022 | 136.17 | N/A | $103.49 | $0.76 |
| 2021 | N/A | N/A | $88.35 | -$0.35 |
| 2020 | 18.58 | N/A | $87.69 | $4.72 |
| 2019 | N/A | N/A | $84.55 | -$0.13 |
| 2018 | N/A | N/A | $85.15 | -$0.44 |
| 2017 | N/A | N/A | $89.17 | -$0.67 |
| 2016 | N/A | N/A | $82.84 | -$3.8 |
| 2015 | N/A | N/A | $104.76 | -$1.07 |
| 2014 | N/A | N/A | $90.4 | -$0.92 |
| 2013 | N/A | N/A | $70.35 | -$1.28 |
| 2012 | N/A | N/A | $49.2 | -$0.95 |
| 2011 | N/A | N/A | $34.38 | -$0.48 |
Biomarin Pharmaceutical PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 40.35 | 23.58% | $56.49 | $1.4 |
| Dec 2025 | 32.65 | 63.99% | $59.43 | $1.82 |
| Sep 2025 | 19.91 | 24.59% | $54.16 | $2.72 |
| Jun 2025 | 15.98 | -37.85% | $54.97 | $3.44 |
| Mar 2025 | 25.71 | -11.98% | $70.69 | $2.75 |
| Dec 2024 | 29.21 | -29.36% | $65.73 | $2.25 |
| Sep 2024 | 41.35 | -32.2% | $70.29 | $1.7 |
| Jun 2024 | 60.99 | -23.89% | $82.33 | $1.35 |
| Mar 2024 | 80.13 | -26.04% | $87.34 | $1.09 |
| Dec 2023 | 108.34 | -5.72% | $96.42 | $0.89 |
| Sep 2023 | 114.91 | -31.06% | $88.48 | $0.77 |
| Jun 2023 | 166.69 | -36.57% | $86.68 | $0.52 |
| Mar 2023 | 262.81 | 93% | $97.24 | $0.37 |
| Dec 2022 | 136.17 | -27.72% | $103.49 | $0.76 |
| Sep 2022 | 188.38 | -34.08% | $84.77 | $0.45 |
BMRN Price vs fair value
BMRN average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
BMRN's current P/E ratio is below the 3, 5 and 10-year averages.
PE comparison
Biomarin Pharmaceutical's P/E of 40.36 is above the Healthcare sector and the industry average. Compared to its Healthcare sector average of 23.78, Biomarin Pharmaceutical's P/E is 70% higher.
BMRN PE vs peers
Compared to its peer stock CPRX, BMRN's PE ratio stands higher.
| Stock name | PE ratio | Market cap |
|---|---|---|
| CPRX Catalyst Pharmaceuticals Inc | 17.35 | $3.84B |
| BMRN Biomarin Pharmaceutical Inc | 40.36 | $10.92B |
| RARE Ultragenyx Pharmaceutical Inc | N/A | $2.83B |
| ESPR Esperion Therapeutics Inc | N/A | $813.48M |
Frequently asked questions
What is Biomarin Pharmaceutical's PE ratio?
The price to earnings ratio for BMRN stock as of Jun 23, 2026, stands at 40.36.
What is the 3-year average PE ratio for Biomarin Pharmaceutical (BMRN)?
The 3-year average PE ratio for BMRN stock is 61.35.
What is the 5-year average PE ratio for Biomarin Pharmaceutical (BMRN)?
The 5-year average PE ratio for BMRN stock is 172.78.
What is the highest PE ratio for BMRN?
Over the last seven years, the quarterly PE ratio reached a historic high of 1,288.17 in the Sep 2021 quarter.
How does the current PE ratio for BMRN compare to its historical average?
BMRN's price to earnings ratio is currently 73% below its 7-year historical average.
How is BMRN's PE ratio calculated (Biomarin Pharmaceutical PE ratio formula)?
To determine the PE ratio, divide the most recent stock price by the TTM earnings per share (EPS). As of today (Jun 23, 2026), Biomarin Pharmaceutical's stock price is $56.5. The earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $1.4. Therefore, Biomarin Pharmaceutical's P/E ratio for today is 40.36. PE RATIO(40.36) = STOCK PRICE($56.5) / TTM EPS($1.4)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.